Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Denosumab
•
Bisphosphonate
•
Endocrinology
•
Primary Care
In a patient with history of atypical femoral fracture while on denosumab how do you sequence further treatment options?
Related Questions
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
How do you approach management of osteoporosis in patients post lung transplant?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Would you consider PTH analogue in a patient with mildly elevated PTH?
